NYT column notes COVID-19 vaccine is latest of many tech transfer successes

NYT column notes COVID-19 vaccine is latest of many tech transfer successes

December 16, 2020

The day after the first COVID-19 vaccine was deployed in the US, a New York Times columnist praised public-private partnerships for their role in the "stunning story of scientific success" and noted that such collaborations have a long history of technological breakthroughs.

David Leonhardt's column, which leads off the publication's The Morning newsletter every weekday, is reprinted here:

Before COVID-19, the record for the fastest vaccine development — for mumps — was four years. Most vaccines have required more than a decade of research and experimentation.

Yet [on December 14], less than a year after the discovery of COVID-19, a critical care nurse in Queens named Sandra Lindsay became the first American to participate in the mass vaccination program for the coronavirus. “I feel like healing is coming,” she said afterward.

It is a stunning story of scientific success.

It also fits a pattern that stretches back decades: Many of the biggest technological breakthroughs in American history have not sprung from the private sector. They have instead been the result of collaboration between private companies and the federal government.

The Defense Department, after all, built the internet. Government research and development also led to transistors, silicon chips, radar, jet airplanes, satellites, artificial limbs, cortisone, flat screens and much more, as MIT economists Jonathan Gruber and Simon Johnson point out in their recent book, “Jump-Starting America.”

“Almost everything about your computer today — and the way you use it — stems from government funding at the early stages,” Gruber and Johnson write.

Why? Because basic research is usually too uncertain and expensive for any one company to afford. Often, it isn’t even clear which future products the research may create. No kitchen appliance company ever would have thought to do the military research that led to the microwave oven.

With COVID-19, the vaccines from both Pfizer and Moderna rely on years of government-funded (and sometimes government-conducted) research into viral proteins and genetics. That research, Kaiser Health News explains, is “the essential ingredient in the rapid development of vaccines in response to COVID-19.”

The federal help accelerated this year. The government funded Moderna’s work in recent months, as part of the billions of dollars it spent to make possible a record-breaking vaccine, The Atlantic’s Ed Yong writes. And while Pfizer turned down direct federal funding, it asked for the government’s help in procuring supplies and also signed a $1.95 billion “advance purchase” agreement with Washington.

As my colleague Neil Irwin has written: “The nine months of the pandemic have shown that in a modern state, capitalism can save the day — but only when the government exercises its power to guide the economy and act as the ultimate absorber of risk. The lesson of COVID capitalism is that big business needs big government, and vice versa.”

What are the lessons for the post-COVID world? Solving the biggest challenges, like climate change, will almost certainly depend on a combination of public-sector funding and private-sector ingenuity.

Yet as Gruber and Johnson note, federal funding of science has become a smaller part of the U.S. economy than it used to be. Which means the COVID-19 vaccine is both an inspiring success and something of an exception. “On its current course,” the economists write, “America seems unlikely to continue its dominance of invention.”

Read more: https://www.nytimes.com/2020/12/15/briefing/attorney-general-barr-sandra...